6 Dec 2020
Novel AML patient selection assay for AMV564, Amphivena’s lead therapeutic in hematology, presented at the 62nd American Society of Hematology (ASH) 2020 Annual Meeting
Author: admintech | Filed under: Press ReleaseSOUTH SAN FRANCISCO, Calif., Dec. 6, 2020 /PRNewswire/ — Amphivena Therapeutics, a clinical-stage oncology company focused on developing immunotherapeutics that restore anti-cancer immunity in patients, today presented data on a novel assay for selection of acute myeloid leukemia (AML)…